Michigan's FY27 Budget Retreats From Innovation - The Biosciences Industry Will Feel The Impact

For more than two decades, Michigan has worked to establish itself as a national leader in innovation. Governors and Legislatures from both parties recognized that economic growth would increasingly be driven not only by traditional manufacturing, but by research, technology commercialization, entrepreneurship, and high-value industries such as the biosciences.

The FY2027 state budget marks a troubling departure from that vision. 

Rather than reinforcing Michigan's innovation economy at a time of unprecedented competition for research, investment, talent, and advanced manufacturing, the budget substantially weakens the state's long-standing commitment to entrepreneurship and commercialization. Dedicated funding for the Entrepreneurship & Innovation (E&I) Program has effectively disappeared, the Michigan Innovation Fund (MIF) once again received no dedicated appropriation, previously approved work project funding was not restored, and no funding was provided to launch Michigan's first statewide biomanufacturing apprenticeship program.  

Instead, lawmakers created a new $68 million Michigan Small Business, Community Growth, and Entrepreneurship Support line item, of which only $9.7 million is designated for entrepreneurship and innovation - far below the $15.7 million previously appropriated for the E&I program alone. Even more concerning, those dollars are no longer tied to the established statutory programs that have successfully supported Michigan's innovation ecosystem for years, leaving considerable uncertainty regarding how the funding will ultimately be allocated and implemented.  

For Michigan's bioscience industry, this is more than disappointing. 

It is difficult to understand. 

The biosciences industry consistently provides some of the highest-paying jobs in Michigan's private sector, supports nearly 48,000 high-skilled employees, attracts hundreds of millions of dollars in venture capital and more than $1 billion annually in NIH research funding, and develops the medicines, medical devices, diagnostics, agricultural technologies, and advanced manufacturing innovations that improve lives while driving economic growth. 

Yet when presented with an opportunity to invest in one of the state's most productive economic sectors, policymakers chose to reduce their commitment. 

The Quiet End of the 21st Century Jobs Fund 

Perhaps the most significant - and least appreciated - change in this year's budget is the sunset of the statutory dedication of tobacco Master Settlement Agreement revenues to Michigan's 21^st Century Jobs Fund. 

Created in 2005, the 21^st Century Jobs Fund represented a bipartisan commitment to diversifying Michigan's economy by investing in knowledge-based industries. Rather than allowing tobacco settlement dollars to disappear into the General Fund, the Legislature dedicated those revenues to building the state's innovation economy through research commercialization, technology transfer, entrepreneurial support, venture capital initiatives, university partnerships, and business acceleration. 

That dedicated funding stream helped create many of the very programs responsible for Michigan's innovation success - including MTRAC, the Technology Transfer Talent Network (T3N), SmartZones, business accelerators, university commercialization efforts, and the Entrepreneurship & Innovation program. 

With the statutory sunset now in effect, those revenues return to the General Fund, where they must compete annually against every other state spending priority. The result is the loss of a predictable, dedicated source of economic development funding that Michigan's innovation ecosystem has relied upon for more than twenty years. As leaders across the state's innovation community have noted, this fundamentally changes how innovation programs will be funded and administered going forward.  

For industries like biosciences - where company formation, product development, and commercialization often span a decade or longer - predictability matters. Entrepreneurs, investors, universities, and manufacturers need confidence that Michigan remains a committed long-term partner. 

An Investment Strategy That Has Proven Its Value 

The irony is that Michigan already knows these investments work. 

Programs supported through Entrepreneurship & Innovation, MTRAC, SmartZones, and T3N have helped launch companies such as HistoSonics, Akadeum Life Sciences, Micro-LAM, and many others that have gone on to attract substantial private investment, create thousands of high-paying jobs, and establish Michigan as a recognized center for innovation. 

These are not isolated success stories—they are the direct result of sustained public-private partnerships designed to move discoveries from Michigan laboratories into Michigan companies. 

The return on investment has never been measured simply by dollars appropriated. It has been measured in startup companies formed, technologies commercialized, venture capital attracted, federal research leveraged, patients served, and communities strengthened. 

Workforce Left Behind 

The budget also missed an opportunity to address one of the industry's greatest competitive challenges. 

Despite widespread recognition that Michigan faces significant shortages of skilled biomanufacturing talent, no funding was included to launch a pilot biomanufacturing apprenticeship program. The $2.06 million initiative would have established Michigan's first registered apprenticeship program dedicated to pharmaceutical, biologics, medical device, and contract manufacturing employers, creating an industry-driven workforce pipeline in Good Manufacturing Practices (GMP), aseptic manufacturing, quality systems, and advanced production technologies. 

At a time when states across the country are investing aggressively in biomanufacturing capacity and workforce development, Michigan chose not to invest in a program that would have strengthened both existing employers and future business attraction efforts. 

The Wrong Message at the Wrong Time 

The timing could hardly be worse. 

Michigan's innovation economy is already navigating uncertainty surrounding federal research funding, technology transfer policy, tariffs, and global competition. At the very moment competitor states are increasing investments in biotechnology, advanced manufacturing, artificial intelligence, and commercialization, Michigan is stepping back from the very funding model that helped build its innovation economy over the last two decades. 

Michigan's elected officials frequently celebrate ribbon cuttings, breakthrough discoveries, startup successes, and announcements of new high-paying jobs. Those achievements deserve recognition - but they do not happen by accident. They are the product of decades of strategic investment in research, entrepreneurship, commercialization, workforce development, and innovation infrastructure. 

One cannot reasonably expect Michigan to remain a national leader in life sciences - indeed, it has been losing ranking consistently over the last decade - while steadily withdrawing the public investments that helped create that leadership. 

For the biosciences industry, the stakes extend well beyond company balance sheets. The sector develops new therapies for patients, strengthens national competitiveness, attracts global investment, creates some of the state's highest-paying careers, and anchors communities across Michigan. 

The advocacy work is far from over, and MichBio will continue working alongside partners throughout the innovation ecosystem to restore a long-term vision for Michigan's economic future. But the FY27 budget should serve as a wake-up call. If Michigan intends to compete for the next generation of life science companies, biomanufacturing facilities, and transformational discoveries, future budgets must once again reflect a sustained commitment to innovation.